After infliximab treatment for IBD patients, the lysis of cell lines expressing TNF-α by the complement-dependent and antibody-dependent cytotoxicity was promoted and reduced inflamed tissue [56]. The gene discussed is TNF; the disease is inflammatory bowel disease.